Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth, Plus Diagnostics to Co-promote Epigenetic Prostate Cancer Test

NEW YORK (GenomeWeb News) – MDxHealth and Plus Diagnostics today announced a co-promotional deal covering MDxHealth's epigenetic test for prostate cancer in the US.

Plus Diagnostics will build awareness for MDx Health's ConfirmMDx test through its national network of urologists. Financial and other terms of the deal were not disclosed.

"The national reach afforded by Plus Diagnostics provides a direct channel to the urology community and will aid in meeting the growing demand for our test," MDxHealth CEO Jan Groen said in a statement.

The epigenetic-based test for distinguishing patients with true negative biopsies from those at risk of occult cancer is performed at MDxHealth's Irvine, Calif., facility and detects an "epigenetic field effect or 'halo' associated with the cancerization process at the DNA level in cells adjacent to cancer foci," the Liege, Belgium-based company said.

Plus Diagnostics is a pathology company with locations in Union, NJ and Irvine.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.